Q-omics provides the consensus-scored KCNMB3 profile across patient tissues and cancer cell-line models. KCNMB3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCNMB3 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, KCNMB3 RNA expression shows 19,889 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where KCNMB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNMB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNMB3 survival associations across molecular data types. KCNMB3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNMB3 RNA expression–survival associations across cancer types. High KCNMB3 expression shows unfavorable associations in KIRC, ACC, COAD, STAD, LGG and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCNMB3 RNA expression.
This table summarizes KCNMB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for KCNMB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNMB3 shows lower tumor expression in THCA and higher tumor expression in BLCA, HNSC, LUAD, LUSC and COAD. The BLCA box plot shows higher KCNMB3 RNA expression in tumor versus normal tissue (log2 FC = +0.481, t-test p < 0.001).
This table shows molecular features associated with KCNMB3 in patient tissues and cancer cell lines. In patient samples, KCNMB3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNMB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and OVARY.
